CURRENT STATUS OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: A CLINICAL PERSPECTIVE